132 related articles for article (PubMed ID: 36281599)
1. [Factors Affecting Adherence to Adjuvant Endocrine Therapy in Japanese Patients with Breast Cancer-An Observational Study].
Omori Y; Osaga S; Shiheido H; Toriguchi N; Iseki C; Bando H
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1077-1086. PubMed ID: 36281599
[TBL] [Abstract][Full Text] [Related]
2. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
[TBL] [Abstract][Full Text] [Related]
3. How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support.
Berkowitz MJ; Thompson CK; Zibecchi LT; Lee MK; Streja E; Berkowitz JS; Wenziger CM; Baker JL; DiNome ML; Attai DJ
J Cancer Surviv; 2021 Feb; 15(1):29-39. PubMed ID: 32804353
[TBL] [Abstract][Full Text] [Related]
4. A mixed-methods study of the technical feasibility and patient acceptability of a real-time adherence monitor in breast cancer survivors taking adjuvant endocrine therapy.
Bright EE; Genung SR; Stanton AL; Arch JJ
Breast Cancer Res Treat; 2022 Oct; 195(3):393-399. PubMed ID: 35962148
[TBL] [Abstract][Full Text] [Related]
5. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer.
Walker HE; Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
J Adolesc Young Adult Oncol; 2016 Mar; 5(1):16-23. PubMed ID: 26812461
[TBL] [Abstract][Full Text] [Related]
6. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.
Quinn EM; Fleming C; O'Sullivan MJ
Ir J Med Sci; 2016 May; 185(2):383-92. PubMed ID: 25971465
[TBL] [Abstract][Full Text] [Related]
8. Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register.
Lundgren C; Lindman H; Rolander B; Ekholm M
Acta Oncol; 2018 Jul; 57(7):935-940. PubMed ID: 29493327
[TBL] [Abstract][Full Text] [Related]
9. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
[TBL] [Abstract][Full Text] [Related]
10. Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income.
Ursem CJ; Bosworth HB; Shelby RA; Hwang W; Anderson RT; Kimmick GG
J Womens Health (Larchmt); 2015 May; 24(5):403-8. PubMed ID: 25884292
[TBL] [Abstract][Full Text] [Related]
11. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
13. A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Harrow A; Dryden R; McCowan C; Radley A; Parsons M; Thompson AM; Wells M
BMJ Open; 2014 Jun; 4(6):e005285. PubMed ID: 24928595
[TBL] [Abstract][Full Text] [Related]
14. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract][Full Text] [Related]
16. Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence.
Wouters H; van Geffen EC; Baas-Thijssen MC; Krol-Warmerdam EM; Stiggelbout AM; Belitser S; Bouvy ML; van Dijk L
Breast; 2013 Oct; 22(5):661-6. PubMed ID: 23770134
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
[TBL] [Abstract][Full Text] [Related]
18. Facing points of view: Representations on adjuvant endocrine therapy of premenopausal patients after breast cancer and their healthcare providers in France. The FOR-AD study.
Roche N; Le Provost JB; Borinelli-Franzoi MA; Boinon D; Martin E; Menvielle G; Dumas A; Rivera S; Conversano A; Matias M; Viansone A; Di Meglio A; Delaloge S; Vaz-Duarte-Luis IM; Pistilli B; Fasse L
Eur J Oncol Nurs; 2023 Feb; 62():102259. PubMed ID: 36623339
[TBL] [Abstract][Full Text] [Related]
19. Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer.
Adachi Y; Oze I; Sawaki M; Hattori M; Yoshimura A; Kotani H; Kataoka A; Sugino K; Horisawa N; Ozaki Y; Endo Y; Nozawa K; Takatsuka D; Iwata H
Breast Cancer; 2021 Sep; 28(5):1087-1095. PubMed ID: 33886077
[TBL] [Abstract][Full Text] [Related]
20. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]